- Home
- NAMS vs RDY Comparison
NAMS vs RDY Comparison
Compare NAMS & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- RDY
- Stock Information
- Founded
- NAMS 2019
- RDY 1984
- Country
- NAMS Netherlands
- RDY India
- Employees
- NAMS N/A
- RDY N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- RDY Biotechnology: Pharmaceutical Preparations
- Sector
- NAMS Health Care
- RDY Health Care
- Exchange
- NAMS Nasdaq
- RDY Nasdaq
- Market Cap
- NAMS 2.2B
- RDY 2.1B
- IPO Year
- NAMS N/A
- RDY N/A
- Fundamental
- Price
- NAMS $18.11
- RDY $14.71
- Analyst Decision
- NAMS Strong Buy
- RDY Buy
- Analyst Count
- NAMS 6
- RDY 1
- Target Price
- NAMS $42.83
- RDY $17.00
- AVG Volume (30 Days)
- NAMS 694.5K
- RDY 1.6M
- Earning Date
- NAMS 05-08-2025
- RDY 05-09-2025
- Dividend Yield
- NAMS N/A
- RDY 0.65%
- EPS Growth
- NAMS N/A
- RDY 1.46
- EPS
- NAMS N/A
- RDY 0.79
- Revenue
- NAMS $47,140,000.00
- RDY $3,809,801,863.00
- Revenue This Year
- NAMS N/A
- RDY $10.24
- Revenue Next Year
- NAMS N/A
- RDY N/A
- P/E Ratio
- NAMS N/A
- RDY $18.43
- Revenue Growth
- NAMS 586.97
- RDY 16.61
- 52 Week Low
- NAMS $14.06
- RDY $12.26
- 52 Week High
- NAMS $27.29
- RDY $16.89
- Technical
- Relative Strength Index (RSI)
- NAMS 47.80
- RDY 63.81
- Support Level
- NAMS $16.79
- RDY $14.24
- Resistance Level
- NAMS $19.58
- RDY $14.77
- Average True Range (ATR)
- NAMS 0.94
- RDY 0.20
- MACD
- NAMS -0.12
- RDY 0.04
- Stochastic Oscillator
- NAMS 47.07
- RDY 95.59
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.